YALE UNIVERSITY
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1701-10-09
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.yale.edu
Clinical Trials
1.7k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1470 trials with phase data)• Click on a phase to view related trials
Life at 100.4: An Immersive Social Virtual Reality (VR) Education Tool for Adolescent and Young Adult Cancer Patients and Caregivers
- Conditions
- CancerAdolescent CancerYoung Adult Cancer
- First Posted Date
- 2025-11-04
- Last Posted Date
- 2025-11-04
- Lead Sponsor
- Yale University
- Target Recruit Count
- 45
- Registration Number
- NCT07224204
- Locations
- 🇺🇸
Pediatric Hematology/Oncology Clinic in Smilow Cancer Hospital, New Haven, Connecticut, United States
Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients
- Conditions
- ObesitySmoking CessationBariatric Surgery Patients
- Interventions
- Drug: Bupropion HCl Extended ReleaseBehavioral: Cognitive-Behavioral Therapy
- First Posted Date
- 2025-11-03
- Last Posted Date
- 2025-11-03
- Lead Sponsor
- Yale University
- Target Recruit Count
- 20
- Registration Number
- NCT07224087
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)
- Conditions
- Alcohol Use DisorderWeight LossBariatric Surgery Patients
- Interventions
- First Posted Date
- 2025-11-03
- Last Posted Date
- 2025-11-03
- Lead Sponsor
- Yale University
- Target Recruit Count
- 10
- Registration Number
- NCT07223983
- Locations
- 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
Shared Decision Making to Treat Or Prevent (STOP) HIV in Justice Populations (R33)
- Conditions
- Substance Use Disorders
- First Posted Date
- 2025-10-31
- Last Posted Date
- 2025-10-31
- Lead Sponsor
- Yale University
- Target Recruit Count
- 400
- Registration Number
- NCT07223398
- Locations
- 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸College of Medicine at the University of Kentucky, Lexington, Kentucky, United States
🇺🇸University of Texas Southwestern Medical Center (UTSW), Dallas, Texas, United States
Single-arm Study of LDART for Stimulant Use Disorder
- Conditions
- Stimulant Use DisorderCocaine Use DisorderMethamphetamine Use Disorder
- First Posted Date
- 2025-10-27
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- Yale University
- Target Recruit Count
- 40
- Registration Number
- NCT07221396
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 336
- Next
News
Google DeepMind's AI Model Discovers Novel Cancer Immunotherapy Approach Through Cell-Level Analysis
Google DeepMind and Yale University unveiled C2S-Scale 27B, a 27-billion-parameter AI foundation model that successfully generated and experimentally validated a novel hypothesis for cancer treatment.
Bexorg Secures $42.5M to Revolutionize CNS Drug Discovery with AI-Powered Whole-Human Brain Platform
Bexorg completed a $23 million Series A financing led by Engine Ventures, bringing total funding to $42.5 million to advance its integrated AI and whole-human brain platform for CNS drug development.
Nilo Therapeutics Emerges from Stealth with $101 Million to Develop Neural Circuit-Based Immunomodulation Therapies
Nilo Therapeutics launched with $101 million Series A financing led by The Column Group, DCVC Bio, and Lux Capital to develop a new class of medicines targeting neural circuits in immune diseases.
CND Life Sciences Receives FDA Breakthrough Device Designation and $3M NIH Grant for Parkinson's Disease Diagnostic Test
CND Life Sciences received FDA Breakthrough Device Designation for its Syn-One Test, a skin biopsy diagnostic tool that demonstrates 95.5% sensitivity in detecting abnormal synuclein in patients with synuclein-associated diseases.
Achieve Life Sciences Appoints Dr. Mark Rubinstein as Interim CMO Amid Cytisinicline FDA Review
Achieve Life Sciences has named Dr. Mark Rubinstein as Interim Chief Medical Officer, succeeding Dr. Cindy Jacobs as the company advances its smoking cessation drug cytisinicline.
Apple Watch Receives FDA Approval for Hypertension Detection Feature, Expected to Identify Over One Million Undiagnosed Cases
Apple's new hypertension notification feature for Apple Watch Series 9 and later models has received FDA approval and will launch with watchOS 26 on September 15.
Early Long COVID Trials of Paxlovid and Monoclonal Antibodies Show No Significant Benefits, But Research Continues
Three prominent clinical trials testing Paxlovid and monoclonal antibodies for Long COVID failed to show significant health improvements compared to placebo groups.
FDA-Approved Asthma Drug Zileuton Shows Promise in Preventing Food Allergy Reactions
Northwestern Medicine researchers discovered that Zileuton, an FDA-approved asthma drug, nearly eliminated life-threatening allergic reactions in mice by blocking a previously unknown pathway involving the DPEP1 gene.
Failed Long COVID Drug Trial Reveals Critical Study Design Flaws as New Company Plans Restart
Berlin Cures' Phase 2 trial of BC 007 (rovunaptabin) for long COVID failed in November 2024 due to poor patient selection and inadequate outcome measures, despite some participants experiencing dramatic symptom improvements.
Yale Researchers Engineer Novel Antibody-RNA Therapy Platform for Treatment-Resistant Cancers
Yale researchers developed TMAB3, a specially engineered antibody that successfully delivers RNA therapies to treatment-resistant "cold" tumors, significantly reducing tumor size and extending survival in animal models of pancreatic, brain, and skin cancers.